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Abstract:  A 21-year-old male patient was admitted to the Emergency room of Dr. Soetomo General Hospital with a 
chief complaint of decrease in consciousness. Jaundice and mental status changes were found. Laboratory 
testing showed hyperbilirubinemia, progressive rise in serum alanine and aspirate aminotransferase levels, 
rise in prothrombin time and International Normalized Ratio (INR), positive IgM anti HAV. Diagnosis of 
this patient was acute liver failure due to acute hepatitis A. The patient was treated treatment with O2 nasal 
3-4 lpm, a low-protein diet, fluid therapy including NaCl 0.9%, dextrose 10% and Branch Chain Amino 
Acids (BCAA), inj. ranitidine 2x1 amp, vitamin K 3x1 amp, FFP transfusion 10 cc/kg (first hour) followed 
by 1 cc/hour, lactulose syrup 4x30 cc, L-ornithine-L-aspartate 4 ampoule/PZ 100 cc for 4 hours. The patient 
was discharged in good condition. Three weeks later, the patient was monitored at the outpatient clinic, and 
jaundice was not found.   
1 INTRODUCTION 
Acute liver failure (ALF) refers to the development 
of severe acute liver injury with encephalopathy and 
impaired synthetic function (INR of ≥ 1.5) in a 
patient without cirrhosis or preexisting liver disease. 
While the time course that differentiates ALF from 
chronic liver failure varies between reports, a 
commonly used cutoff is illness duration of <26 
weeks. ALF can be subcategorized based on how 
long the patient has been ill and various cutoffs have 
been used. ALF is classified as hyper acute (<7 
days), acute (7 to 21 days), or subacute (>21 days 
and <26 weeks). ALF has also been referred to as 
fulminant hepatic failure, acute hepatic necrosis, 
fulminant hepatic necrosis, and fulminant hepatitis. 
Untreated, the prognosis is poor; thus, the 
recognition and management of patients with ALF is 
crucial (Chopra, 2015).  
Hepatitis A is a disease of the liver caused by the 
hepatitis A virus (HAV). HAV is a single-stranded 
RNA virus, a member of the Hepatovirus genus of 
the Picornaviridae family. HAV causes an acute 
self-limiting illness, usually spread through the 
fecal-oral route of transmission. Cases occur most 
frequently among children and young adults. Rarely, 
a person may develop fulminant  hepatitis A, which 
is characterized by severe symptoms and may be 
fatal (Cheney, 2015).   
The incidence of ALF in developed countries is 
between one and six cases per million people per 
year. The incidence rate may be higher in 
developing countries, but the data are lacking. The 
etiology of ALF varies demographically (Panackel, 
2015). In Australia, Denmark, the United Kingdom, 
and the United States, acetaminophen is the most 
common cause of ALF, whereas in Asia and some 
other parts of Europe, viral hepatitis predominates 
(Chopra, 2015).  
Hepatotropic viruses are the most common cause 
of ALF in developing countries.  ALF occurs in 
<1% of cases of acute hepatitis A (Panackel, 2015).  
The majority of acute hepatitis A infections do not 
result in ALF, and many young patients with acute 
hepatitis A are anicteric and asymptomatic (Torres, 
2010). Although ALF due to hepatitis A is very rare, 
it needs a deeper understanding; thus, we report a 
case of a young male with ALF caused by acute 
hepatitis A.  
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2 CASE 
A male, Mr. MR, 21 years old, single, Moslem, 
Makassarese, lives in Surabaya, currently receiving 
education in “Akademi Penerbangan” (patient was 
staying in a dormitory during his education), was 
referred by Bhayangkara Hospital to the Emergency 
room of Dr. Soetomo General Hospital on August 
13, 2015 with a chief complaint of decrease in 
consciousness.  
The patient’s consciousness had decreased, 
starting with confusion 12 hours before he was 
referred to Dr. Soetomo General Hospital. 
Previously, his vision was blurry one day before he 
was referred to Dr. Soetomo General Hospital and 
he lost his sight a few hours later. The patient had 
been feverish for 5 days, his eyes turned yellow for 3 
days, he felt nausea with vomiting and abdominal 
discomfort, plus loss of appetite (+). He had noticed 
that his urine was much darker than normal. There 
was no complaint with defecation. The patient 
underwent a medical examination in Bhayangkara 
Hospital and was hospitalized there for 3 days. 
Bhayangkara Hospital diagnosed him with hepatitis 
A. The patient was then referred to Dr. Soetomo 
General Hospital because his condition continuously 
declined and he lost his sight.  
He had no history of diabetes mellitus, 
hypertension, smoking, drug abuse, or liver disease. 
The family history of diabetes mellitus and 
hypertension was not found. No other family 
members had a similar disease. His general 
condition was weak, the patient was confused with a 
GCS of 3-4-5, blood pressure of 160/96 mmHg, 
regular pulses of 90 bpm, respiration of 22 bpm and 
axillary temperature of 37.5°C. Examination of the 
head and neck showed jaundice, no anemia, 
cyanosis, and dyspnea and no lymph node 
enlargement. Examination of the thorax found 
symmetrical breathing movements, right and left 
vesicular breath sounds, and no rhonchi or 
wheezing. On cardiac examination, the apex beat 
was palpated in the 5th intercostal space of the left 
midclavicular line, S1 and S2 were single and no 
murmurs, with no gallops or extra-systole. On 
abdominal examination, normal positive bowel 
sounds were found, the liver was palpable one finger 
below the right costal arch and the spleen was not 
palpable, plus tenderness was found on right upper 
abdominal quadrant. On extremity examination, the 
acral areas were warm, dry red, and there was no leg 
edema.  
Laboratory examination (August 13th 2015): Hb 
14.3 g/dL, leukocytes 13.560/uL, neutrophils 58.8%, 
thrombocytes 303,000/uL, HCT 45%, random blood 
glucose 80 mg/dL, serum creatinine 1.12 mg/dL, 
BUN 16 mg/dL, direct bilirubin 7.29 mg/dL, total 
bilirubin 11.43 mg/dL, ALT 1867 IU/L, AST 371 
IU/L, albumin 3.4 g/dL, CRP 1.72 mg/L, potassium 
4.17 mmol/L, sodium 132.1 mmol/L, chloride 95.5 
mmol/L, HbsAg: non-reactive, PPT 41.7 seconds 
(control 11), APTT 86.5 seconds (control 26.1), IgM 
anti HAV (+). Urinalysis: SG 1.015, pH 6.5, prot 
(+1), glu (-), keton (-), nitrite (-), leukocyte (-), 
urobilinogen (+2), bilirubin (+2). Blood gas 
analysis: pH 7.53, pCO2 35, pO2 99, HCO3 29.2, 
Beecf 6.5, SO2 98%.                                              
Chest X-ray: cor and pulmo were within normal 
limits. Abdominal ultrasonography imaging: Hepar: 
normal size, regular edge, sharp angle, echo 
parenchyma intensity was homogeneous. Portal vein 
and hepatic vein appeared normal. IHBD/EHBD had 
no enlargement. Mass/cyst/abscess (–). Conclusion: 
no visible abnormalities. Consultation to 
Ophthalmology Department: oculi right and sinistra: 
visus: difficult to evaluate. Conclusion: normal 
fundus. Suggestion: re-consultation if the condition 
is adequate. Consultation to Neurology Department:  
signs of neurological deficit: not found, meningeal 
sign: not found. Based on anamnesis, history of 
illness, clinical, laboratory and adjunctive 
examination, the patient was diagnosed with acute 
liver failure e.c. acute hepatitis A. Planning of 
diagnosis: anti HCV, serial liver function tests, serial 
RBG, PPT and APTT. Planning of therapy: O2 nasal 
3-4 lpm, EH diet III 1,200 kcal/day (start with sonde 
6x100 cc), IVFD NaCl 0.9% : D10% : BCAA 1:1:1 
21 dpm, inj. cefotaxime 3x1 gram iv, inj. ranitidine 
2x1 amp iv, inj. metoclopramide 3x1 amp iv, inj. 
vitamin K 3x1 amp, UDCA 3x250 mg p.o., 
hepatoprotector 3x1 p.o., lactulose syrup 4x 30 cc. 
Planning of monitoring: complaint and vital sign.  
2nd day of admission: S:  decrease in 
consciousness, with a GCS of 3-4-5, blurred vision. 
O: blood pressure 140/90 mmHg, pulse 82 
beats/minutes, respiratory rate 20x/minutes, 
temperature 37.0oC, jaundice. Consultation to 
Psychiatry Department. Conclusion: the lucid phase 
of delirium and organic mental disorder. A: acute 
liver failure e.c. acute hepatitis A. Planning of 
diagnosis: Consultation to Ophthalmology 
Department, ALT, AST, direct bilirubin, indirect 
bilirubin/3 days, serial RBG, PPT and APTT post 
FFP, rapid diagnostic serological tests (Lepto Tek), 
procalcitonin, blood and urine culture. Planning of 
therapy:   
The patient’s treatments were the same as the 
day before, with added Fresh Frozen Plasma (FFP) 
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transfusion 450 cc/hour followed by 150 cc/3 hours, 
L-ornithine-L-aspartate 4 ampoule/PZ 100 cc for 4 
hours. Planning of monitoring: complaint and vital 
signs.  
3rd day of admission: S:  general condition was 
weak, with a GCS of 4-5-6, blurred vision. O: blood 
pressure 150/90 mmHg, pulse 78 beats/minutes, 
respiratory rate 20x/minutes, temperature 37.0oC, 
jaundice. PPT 31.6 seconds (9-12), APTT 85.0 
seconds (23-33), RBG 101 mg/dl, IgG leptospira 
negative, IgM leptospira negative, anti HCV non-
reactive, procalcitonin 2.11. A: acute liver failure 
e.c. acute hepatitis A. Planning of diagnosis: RBG, 
PPT and APTT post FFP. Planning of therapy: The 
patient’s treatments were the same as the day before. 
Planning of monitoring: complaint and vital signs.  
4th day of admission: S: general condition was 
weak, with a GCS of 4-5-6. The patient underwent 
improvement, with the blurred vision getting better. 
O: blood pressure 150/90 mmHg, pulse 76 
beats/minutes, respiratory rate 20x/minutes, 
temperature 36.5oC, jaundice. RBG 98 mg/dl, PPT 
22.6 seconds (9-12), APTT 62.9 seconds (23-33), 
INR 2.06. ALT 555 IU/L, AST 92 IU/L. 
Consultation to Ophthalmology Department: The 
ophthalmoscopy examination: fundus reflex +/+, 
retinal bleeding -/-, exudate -/-, retinal 
microaneurysm -/-, macular reflex +/+. Conclusion: 
the retina, blood vessels, and the optic disc appeared 
normal. Planning of diagnosis: PPT and APTT post 
FFP. Planning of therapy: H2 diet 2,100 kcal/day, 
the patient’s treatments were the same as the day 
before, with added Fresh Frozen Plasma transfusion 
450 cc/1 hour followed by 150 cc/3 hours.  
5th day of admission: S: the general condition 
was adequate; the patient was compos mentis with a 
GCS of 4-5-6, and blurred vision was getting better. 
O: blood pressure 140/90 mmHg, pulse 74 
beats/minutes, respiratory rate 20x/minutes, 
temperature 36.5oC, jaundice. RBG 91 mg/dL, PPT 
16.5 seconds (9-12), APTT 38.6 seconds (23-33), 
INR 1.51. Review of ultrasonography imaging with 
conclusion: hepatomegaly and gallbladder sludge. 
Planning of diagnosis: toxicology. Planning of 
therapy: IVFD D10%: BCAA 2:1 21 dpm. Other 
therapies continued.  
7th day of admission: S: the general condition 
was adequate; the patient was compos mentis with a 
GCS of 4-5-6, and the blurred vision was getting 
better. O: blood pressure 120/80 mmHg, pulse 70 
beats/minutes, respiratory rate 20x/minutes, 
temperature 36.5oC, jaundice. Laboratory 
examination result: Hb 14.6 g/dL, leukocytes 
15,090/uL, neutrophils 67.9%, thrombocytes 
305,000/uL, HCT 42%, random  blood glucose  87 
mg/dL, serum creatinine 0.5 mg/dL, BUN 16 mg/dL, 
direct bilirubin 8.7 mg/dL, total bilirubin 13.07 
mg/dL, ALT 336  IU/L, AST 113 IU/L, albumin 3.4 
g/dL, CRP 0.4 mg/L, potasium 4.12 mmol/L, 
natrium 136 mmol/L, chloride 96 mmol/L, PPT 12.6 
seconds (9-12), APTT 38.9 seconds (23-33), INR 
1.16.  
Toxicology test: negative. Planning of therapy: 
the patient’s treatments were the same as the day 
before.  
10th day of admission: S: the general condition 
was adequate; the patient was compos mentis with a 
GCS of 4-5-6. O: blood pressure 120/80 mmHg, 
pulse 70 beats/minutes, respiratory rate 20x/minutes, 
temperature 36.5oC, jaundice. Laboratory 
examination result: Hb 13.7 g/dL, leukocytes 
10,020/uL, neutrophils 63.9%, thrombocytes 
260,000/uL, HCT 40.3%, random blood glucose 102 
mg/dL, direct bilirubin 8.98 mg/dL, total bilirubin 
14.96 mg/dL, ALT 226 IU/L, AST 98 IU/L, blood 
and urine culture: sterile. Planning of therapy: the 
patient’s treatments were the same as the day before.  
12th day of admission: No complaint of the 
condition. Blood pressure 120/80 mmHg, pulse 82 
beats/minutes, respiratory rate 20x/minutes, 
temperature 36.5oC, jaundice. Laboratory 
examination result: direct bilirubin 7.14 mg/dL, total 
bilirubin 11.72 mg/dL, ALT 145 IU/L, AST 91 
IU/L. Patient was discharged and suggested to visit 
Gastroenterohepatology policlinic the next week.  
The patient was treated with a vitamin K 3x100 mcg 
p.o., UDCA 3x250 mg p.o., hepatoprotector 3x1 
p.o., L-ornithine-L-aspartate 3x2 sachet.  
A week after being discharged, the patient came 
to the clinic in a better condition, and the laboratory 
result was: random blood glucose 121 mg/dL, direct 
bilirubin 5.41 mg/dL, total bilirubin 9.17 mg/dL, 
ALT 81 IU/L, AST 45 IU/L. Three weeks later, the 
patient was monitored at the outpatient clinic, and 
jaundice was not found. The laboratory result: direct 
bilirubin 0.91 mg/dL, total bilirubin 1.26 mg/dL, 
ALT 48 IU/L, and AST 36 IU/L.  
3 DISCUSSION 
As mentioned above, ALF occurs on the basis of 
acute hepatocellular injury caused by toxic, viral or 
metabolic stress or hypotension. However, 
regardless of the initial type of liver injury, ALF 
propels a series of events inducing hepatocellular 
necrosis and apoptosis, reducing the regeneration 
capacity of the liver. Massive loss of hepatocytes 
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reduces the functional capacity of the liver for 
glucose, lipid and protein metabolism, 
biotransformation, and synthesis of coagulation 
factors, leading to encephalopathy, coagulopathy, 
hypoglycemia, infections, and renal and multi-organ 
failure (Altinbas, 2015). The initial clinical 
presentation of ALF is often nonspecific and easily 
misdiagnosed, as it often occurs in otherwise healthy 
individuals without a history of chronic liver disease 
(Torres, 2010).  The clinical presentation of ALF 
varies, and symptoms can range from mild 
gastrointestinal confusion to generalized malaise to 
confusion (Cox, 2009). Malaise, fatigue, nausea 
and/or vomiting usually appear first, followed by 
jaundice. Mental status changes usually appear after 
the onset of jaundice (Torres, 2010). Other clinical 
manifestations may include hepatomegaly, lethargy, 
anorexia, pruritus, right upper quadrant tenderness, 
and abdominal distension from ascites.  As the liver 
failure progresses, patients who were initially 
anicteric may develop jaundice, and those with 
subtle mental status changes (e.g. lethargy, difficulty 
sleeping) may become confused or eventually 
comatose (Chopra, 2015).  
 Laboratory test abnormalities are typically seen 
in patients with acute liver failure including: 
Prolonged prothrombin time, resulting in an INR ≥ 
1.5 (this finding is part of the definition of acute 
liver failure and thus must be present); elevated 
aminotransferase levels (often markedly elevated); 
elevated bilirubin level; low platelet count (≤ 
150,000/mm3). Other laboratory findings that can be 
seen in patients with ALF include: anemia, elevated 
serum creatinine and blood urea nitrogen, elevated 
amylase and lipase, hypoglycemia, 
hypophosphatemia, hypomagnesemia, hypokalemia, 
acidosis or alkalosis, elevated ammonia level, 
elevated lactate dehydrogenase (LDH) level 
(Chopra, 2015). The liver has a central role in the 
synthesis of most coagulation factors and some 
inhibitors of coagulation and fibrinolysis. 
Deficiencies of fibrinogen, factors II, V, VII, IX and 
X, and platelet are often present in ALF (Munoz, 
2010). The synthesis of coagulation factors is 
universally decreased, while consumption of clotting 
factors and platelets also may occur; thus, platelet 
counts frequently drop to ≤ 150,000/mm3 (50-70%) 
(Lee, 2011).  
Hepatic encephalopathy is a common 
complication in patients with ALF. The altered 
sensorium that occurs in ALF is believed to be 
caused by abnormalities in the regulation of 
neurotransmitters (Cox, 2009).  Arterial ammonia 
levels rise and appear to contribute to astrocyte 
swelling. Levels greater than 150 to 200 mmol/L 
have been shown to correlate with cerebral edema 
and herniation (Tujios, 2011). Intracranial 
hypertension from severe cerebral edema remains a 
feared complication and is a leading cause of death 
worldwide among patients with ALF. About 50–
80% of ALF patients have renal failure. Drug-
induced nephrotoxicity; acute tubular necrosis; and 
abdominal compartment syndrome are the main 
causes (Panackel, 2015).  This complication is more 
common in the elderly and in patients with 
acetaminophen-induced ALF. Circulatory 
dysfunction and hypotension are common in patients 
with ALF (Bernal, 2013).   
 
 
Figure 1: Acute liver failure involvement of multiple 
organ systems (Torres, 2010). 
In this case, the patient was referred to the 
Emergency room of Dr. Soetomo General Hospital 
with a chief complaint of decrease in consciousness. 
There was no impairment of the liver previously.  
No alcohol and medications were used over the last 
6 months. The patient showed mental disorientation 
or confusion, with clinical features of fever and 
jaundice. He felt nausea, vomiting and abdominal 
discomfort. From abdominal examination, the liver 
was palpable one finger below the right costal arch, 
and tenderness was found on the right upper 
abdominal quadrant. Laboratory testing showed 
elevated aminotransferase and bilirubin levels, 
prolonged prothrombin time with an INR ≥ 1.5. 
Based on anamnesis, physical examination and 
laboratory findings, the patient was diagnosed with 
acute liver failure. 
Acute liver failure can result from a wide variety 
of causes. Several viruses have been associated with 
ALF, including hepatitis A, B, C, D, and E (Chopra, 
2015). HAV is the second most common viral cause 
of ALF after HBV (Ichai, 2008).   
 
 
IMRM 2017 - International Meeting on Regenerative Medicine
392
Table 1: Etiologies of Acute Liver Failure (Altinbas, 2015). 




Drug concetrations in serum  
History 
Drug concentrations in serum/eosinophil count








HBsAG, IgM anti-core, HBV DNA 
HBsAG, IgM HDV, HDV RNA 
Anti-HCV, HCV RNA 
Anti-HEV, HEV RNA 
Immunologic Autoimmune  
 
GVHD 
ANA,LKM, SLA, ASMA, IgG 
Biopsy 






Urinary copper, ceruloplasmin in serum, slit-lamp 
examination 
AT level in serum, AT genotyping 
Ferrintin in serum, transferrin saturation 






Ultrasound (Doppler), echocardiography (ECO) 
Ultrasound (Doppler) 
Pregnancy-included HELLP syndrome Hematocrit test, peripheral blood smear, platelet 
count
ANA, anti-nuclear antibody; ASMA, anti-smooth muscle antibody;IgM, immunoglobulin M; IgG, immunoglobulin G; 
HBsAg, hepatitis B surface antigen 
Hepatitis A infection has four clinical phases 
although these do not occur in all patients. The first 
stage is an incubation period of 15 to 50 days (mean 
28 to 30 days). This stage is asymptomatic, but the 
infected person may be actively shedding the virus 
in the stools. The second stage is a pre-icteric period 
of several days to weeks that may precede the onset 
of jaundice. This prodromal period is characterized 
by nonspecific symptoms followed by 
gastrointestinal symptoms such as anorexia (loss of 
appetite), nausea, vomiting, abdominal pain, fatigue, 
malaise, and fever. Other symptoms at this stage 
may include myalgia (muscle pain), arthralgia (joint 
pain), coughing, pharyngitis, constipation, diarrhea, 
pruritus (itchiness), and urticaria (hives). Dark urine 
caused by elevated bilirubin levels usually occurs 
prior to the onset of jaundice. In the third stage, 
yellowing of the skin and eyes of jaundice appears 
and most symptoms subside, although clinical signs 
such as hepatomegaly and hepatic tenderness are 
found in about half of patients. Jaundice usually 
resolves within a few weeks. The final stage is a 
convalescent period during which the patient 
recovers (WHO, 2010). The clinical course of HAV 
infection varies greatly, ranging from asymptomatic, 
subclinical infections to cholestatic hepatitis or 
fulminant liver failure (Pischke, 2015).  
The diagnosis of acute HAV infection is made by 
the detection of anti HAV antibodies in a patient 
with the typical clinical presentation. Serum IgM 
anti HAV is the gold standard for the detection of 
acute illness. The presence of serum IgM anti HAV 
antibodies in adults without clinical features of viral 
hepatitis does not necessarily indicate acute 
infection. Anti HAV is positive at the onset of 
symptoms, peaks during the acute or early 
convalescent phase of the disease, and remains 
positive for approximately four to six months.  IgG 
anti HAV appears early in the convalescent phase of 
the disease and remains detectable for decades 
(Cheney, 2015).  
  In this case, a 21-year old man presented with a 
5-day history of fever, nausea, vomiting, upper 
abdominal discomfort, and loss of appetite. He had 
noticed that his urine was much darker than normal. 
On examination, he was jaundiced, the liver was 
palpable one finger below the right costal arch, and 
tenderness was found on the right upper abdominal 
quadrant. IgM anti HAV were positive, with raised 
liver enzyme levels. HbsAg (-), anti HCV (-). Acute 
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hepatitis A was diagnosed and confirmed by 
anamnesis, physical examination and laboratory 
findings. Acute hepatitis A is mostly self-limiting. 
Factors which affect the severity of viral hepatitis A 
consist of host and viral factors. For the viral factors, 
genetic variation of 5’ nontranslated region (NTR) is 
related to the severity of the disease whereas the 
genotype of HAV has no relation to the severity of 
acute hepatitis A. The host factors such as 
underlying chronic liver disease, old age, heavy 
alcohol drinking, HIV infection, pregnancy, etc. are 
suggested (Kim, 2010).  
Specific treatment is not available for acute 
hepatitis A virus infection. As in most cases, the 
infection is self-limiting and is followed by complete 
recovery without chronic sequelae, and no specific 
interventions are required. Treatment and 
management of HAV infection are supportive. 
Treatment of acute viral hepatitis involves resting, 
relieving symptoms and maintaining adequate intake 
of fluids (CDC, 2015). During the acute period, 
general measures such as a healthy diet, plenty of 
fluids and adequate rest can help an individual to 
feel better. Hospitalization is warranted for patients 
whose nausea and vomiting places them at risk of 
dehydration. Patients who develop fulminant 
infection require aggressive supportive therapy and 
should be transferred to a center capable of 
performing liver transplantation (Cheney, 2015).  
 In this case, fluid therapy for this patient was 
normal saline (NaCl 0.9%), and he was also given 
supportive therapy including ranitidine and 
metoclopramide.  
The general management consists of intensive 
care support, treatment of specific etiologies and 
early detection of candidates for liver 
transplantation. Special attention should be given to 
coma care, fluid management, hemodynamics, 
metabolic parameters, and infection control 
(Panackel, 2015).  Patients with grade I 
encephalopathy may be managed on a general 
medical ward, quiet environment and frequent 
neurologic checks (e.g. every two hours) are 
performed. If there is progression to grade II 
encephalopathy, or for patients with grade II, III, or 
IV encephalopathy, management in an intensive care 
unit is indicated. Serial laboratory tests are used to 
follow the course of a patient's liver failure and to 
monitor the complications. Serum aminotransferases 
and bilirubin should be monitored daily. More 
frequent monitoring (three to four times daily) 
should be performed for coagulation parameters, 
complete blood counts, metabolic panels, and 
arterial blood gases. In particular, patients should be 
monitored and treated for hypoglycemia, 
hypokalemia, hypomagnesemia, and 
hypophosphatemia (Chopra, 2015).  
Hemodynamic derangements are common in 
patients with ALF due to low systemic vascular 
resistance. In addition, patients may have 
intravascular volume depletion because of decreased 
oral intake and extravasation of fluid into the 
extravascular space. As a result, most patients will 
require fluid resuscitation initially. Patients who are 
hypotensive should be resuscitated with normal 
saline. Some patients may not respond adequately to 
fluid resuscitation and may require vasopressor 
support. Norepinephrine is often preferred because it 
is considered as the best augmentation of peripheral 
organ perfusion with less tachycardia and better 
preservation of splanchnic blood flow than other 
agents. Dextrose should be added to crystalloid 
solutions in patients with hypoglycemia (Chopra, 
2015). Early restoration of intravascular volume and 
systemic perfusion can prevent multiorgan failure 
(Panackel, 2015). Hypoglycemia and hyperglycemia 
should be avoided in patients with ALF. Glucose 
should be monitored every 2–6 hours. If the glucose 
level is below 100 mg/dL, D10 infusion is conducted 
to maintain  a serum glucose level above 100 mg/dL 
and less than 140– 180 mg/dL (Patton, 2012). 
Branched-chain amino acids (BCAA) are used as a 
therapeutic nutritional supplement in patients with 
cirrhosis and hepatic encephalopathy (Altinbas, 
2015).  
ALF is an immunocompromised state due to 
dysfunction of monocytes, neutrophils, kupffer cells, 
and complementary systems. ALF is a state of 
functional immunosuppression that carries a high 
risk of sepsis. Most common infections are bacterial 
pneumonia, urinary tract infection, intravenous 
catheter-induced sepsis, and spontaneous bacterial 
peritonitis. Fungal infections occur in 30% of 
patients with ALF. Frequent sputum, blood and 
urine culture should be done to detect infection 
early. Broad spectrum antibiotics may be 
administered preemptively in patients with 
coagulopathy, grade III or IV encephalopathy or 
multiorgan failure (Panackel, 2015). If the decision 
is made to provide empiric broad spectrum antibiotic 
coverage, nephrotoxic antibiotics, particularly 
aminoglycosides, and hepatotoxic antibiotics should 
be avoided (Chopra, 2015).    
Nutritional support is a vital component in the 
treatment of ALF and should be initiated early. It is 
required to prevent catabolism of body stores of 
proteins and it may decrease the risk of 
gastrointestinal bleeding from stress ulceration in 
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critically ill patients. To prevent protein catabolism, 
severe protein restrictions should be avoided; a daily 
intake of 60 grams of protein is reasonable for most 
patients with ALF (Chopra, 2015).  Protein 
restriction is not indicated, and 1 g/kg per day of 
protein is recommended (Torres, 2010). In patients 
with grade I or II encephalopathy, oral or enteral 
feeding is usually sufficient to meet metabolic 
requirements. Enteral feeding should be provided for 
patients with grade III or IV encephalopathy. If 
adequate enteral feeding cannot be provided, 
parenteral nutrition should be initiated (Chopra, 
2015).    
Ammonia-lowering therapy with lactulose has 
been the mainstay of treatment for HE (Torres, 
2010). Lactulose should be administered at a dose of 
30–60 mL given orally or via a nasogastric tube 
every 2–6 hours. In patients without good response 
to oral lactulose or with clinical concerns of ileus, an 
alternative approach is to administer lactulose via a 
150-mL enema plus 350 mL of tap water every 6–8 
hours (Patton, 2012). Cerebral edema and ICH are 
the most dramatic complications of ALF. Mannitol 
therapy (0.5-1 g/kg) has been shown to improve 
survival. Recommended management includes 
intubation, sedation, and head-of-bed elevation to at 
least 30 degrees to prevent aspiration pneumonia. 
Sedation with Propofol is preferred as it may lower 
intracranial pressure (Tujios, 2011).  Head elevation, 
induction of hypothermia and hyperventilation are 
recommended by some experts in patients with 
increased ICP. With worsening brain edema, 
patients present with systemic hypertension and 
bradycardia (Cushing reflex), dilated and fixed 
pupils, and in the end respiratory arrest. Clinical 
signs of elevated ICP (systemic hypertension, 
bradycardia and irregular respirations–Cushing’s 
triad) are not uniformly present, and other 
neurological changes such as pupillary dilatation or 
signs of decerebration are typically evident only late 
in the course. L-ornithine L-aspartate (LOLA) 
reduces ammonia levels by increasing hepatic 
ammonia disposal and its peripheral metabolism 
(Altinbas, 2015).  
Clinically significant spontaneous bleeding 
occurs in approximately 5% of ALF patients. 
Coagulopathy is managed by routine intravenous or 
subcutaneous vitamin K. Fresh frozen plasma, 
cryoprecipitate and platelets are given for INR at or 
above 1.5, fibrinogen less than 100 mg/dL and 
platelets less than 50,000/mm3 but only if there is 
active bleeding or prior to invasive procedures 
(Tujios, 2011). Stress ulcer prophylaxis with an H2 
blocker or proton pump inhibitor is to be given to all 
patients with ALF, because the most common site of 
bleeding is the gastrointestinal tract (Panackel, 
2015). In cholestatic diseases, the retention of toxic 
bile acids leads to cell injury. The UDCA counters 
this effect by stimulating hepatocytes and bile duct 
epithelial cells to secrete bile. The UDCA at 13-15 
mg/kg/day is approved for treatment of primary 
biliary cirrhosis by the United States Food and Drug 
Administration, and UDCA is the only disease-
modifying agent recommended by the American 
Association for the Study of Liver Disease 
(AASLD) for primary biliary cirrhosis. UDCA has 
antioxidative, cytoprotective and anti-apoptotic 
effects by reducing cytolysis of hepatocytes. 
Furthermore, UDCA alter the bile acid pool, thus 
altering the balance between toxic hydrophobic and 
non-toxic bile salts (Beuers, 2015).   
 In this case, therapy for this patient included O2 
nasal 3 lpm, and EH diet II 1,400 kcal/day. On the 
fourth day of treatment, after the patient was 
conscious, diet was converted to a H2 diet 2,100 
kcal/day. The patient was also given normal saline 
(NaCl 0,9%), dextrose 10% and branched-chain 
amino acids (BCAA), inj. cefotaxime 3x1 gram iv, 
inj. ranitidine 2x1 amp iv, inj. metoclopramide 3x1 
amp iv, inj. vitamin K 3x1 amp, UDCA 3x250 mg 
p.o., hepatoprotector 3x1 p.o., lactulosa syrup 4x30 
cc, fresh frozen plasma (FFP) transfusion 450 cc/1 
hour followed by 150 cc/3 hours, L-ornithine-L-
aspartate 4 ampoule/PZ 100 cc for 4 hours. 
Complete blood count, serum aminotransferases and 
bilirubin were monitored every 3 days.  
Overall, survival rates in patients treated for ALF 
are greater than 60%. Approximately 40% of 
patients will survive without needing a liver 
transplantation. The prognosis of patients who are 
listed for transplantation is variable and cannot 
always be predicted accurately. Following liver 
transplantation, the one-year survival rate is 
approximately 80%. The majority of deaths among 
patients who encounter liver transplantation are due 
to neurologic complications or sepsis which occur 
within three months of the transplantation (Chopra, 
2015). Multiple prognostic models have been 
proposed to help determine the likelihood of 
spontaneous survival. The most widely applied 
prognostic system is the King’s College Hospital 
criteria (KCH Criteria). These criteria incorporate 
both the etiology of ALF and clinical parameters of 
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Table 2: King’s College Criteria. 
Acetaminophen-induced ALF 
Arterial pH<7.3 (regardless of HE) 
OR all 3 of the following 
- INR>6.5 
- Creatine>300μ mol/l 
- He grade 3-4 
Non-Acetaminophen-induced ALF 
INR>6.5 (regardless of HE) 
OR all 3 of 5 of the following (regardless of HE) 
- Age <10 or >40 years 
- Etiology: indeterminated, drug-induced 
- Time interval icterus to encephalopathy 
>7days 
- INR>3.5 
- Bilirubin >3000μ mol/l 
 
Approximately 85% of HAV-infected 
individuals have full clinical and biochemical 
recovery within three months and nearly all have 
recovered in six months. Serum aminotransferase 
concentrations decrease more rapidly than the serum 
bilirubin. The latter normalizes in more than 85% of 
individuals by three months. Although prognosis of 
acute hepatitis A is generally favorable, a minority 
of patients are accompanied by fatal complications 
(Cheney, 2015).  
In this case, the patient was discharged from the 
hospital in a better clinical condition, even though 
still having jaundice, but the trend demonstrated 
decreasing bilirubin. Treatment was continued with 
vitamin K 3x100 mcg p.o., UDCA 3x250 mg p.o., 
hepatoprotector 3x1 p.o., Lornithine-L-aspartate 3x2 
sachet. The patient was suggested to rest at home. 
The patient was also requested to visit the 
Gastroenterohepatology policlinic timely. 
4 SUMMARY 
Diagnosis of this patient was acute liver failure due 
to acute hepatitis A. The patient was treated with O2 
nasal 3-4 lpm, a low-protein diet, fluid therapy 
including NaCl 0.9%, dextrose 10% and Branch 
Chain Amino Acids (BCAA), inj. ranitidine 2x1 
amp, vitamin K 3x1 amp, FFP transfusion 10 cc/kg 
(first hour) followed by 1cc/hour, lactulose syrup 
4x30 cc, L-ornithine-L-aspartate 4 ampoule/PZ 100 
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